Andreas Krämer

Andreas Krämer

SGC Frankfurt

Krämer

Andreas Krämer

Affiliations

Biography

Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group led by Stefan Knapp at the SGC Frankfurt as a postdoc, where he was funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer. Afterwards he worked at the Frankfurt Cancer Institute (FCI) as a staff scientist where, among other things, he was responsible for developing a comprehensive screening platform for kinases. In the beginning of 2022, Andreas became a principal investigator and is responsible for running the X-ray crystallography facility unit. His current research interests focus primarily on the structural biology of kinases and E3 ligases.

2022

Aurora Kinase A Is Involved in Controlling the Localization of Aquaporin-2 in Renal Principal Cells.

Baltzer S, Bulatov T, Schmied C, Krämer A, Berger BT, Oder A, Walker-Gray R, Kuschke C, Zühlke K, Eichhorst J, Lehmann M, Knapp S, Weston J, von Kries JP, Süssmuth RD, Klussmann E

Int J Mol Sci. 2022-1-11 . 23(2): .doi: 10.3390/ijms23020763

PMID: 35054947

2021

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders.

Dölle A, Adhikari B, Krämer A, Weckesser J, Berner N, Berger LM, Diebold M, Szewczyk MM, Barsyte-Lovejoy D, Arrowsmith CH, Gebel J, Löhr F, Dötsch V, Eilers M, Heinzlmeir S, Kuster B, Sotriffer C, Wolf E, Knapp S

J Med Chem. 2021-5-13 . .doi: 10.1021/acs.jmedchem.1c00146

PMID: 33980013

Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Wells CI, Drewry DH, Pickett JE, Tjaden A, Krämer A, Müller S, Gyenis L, Menyhart D, Litchfield DW, Knapp S, Axtman AD

Cell Chem Biol. 2021-1-11 . .doi: 10.1016/j.chembiol.2020.12.013

PMID: 33484635

2020

Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis.

Wanior M, Preuss F, Ni X, Krämer A, Mathea S, Göbel T, Heidenreich D, Simonyi S, Kahnt AS, Joerger AC, Knapp S

J Med Chem. 2020-12-10 . 63(23):14680-14699 .doi: 10.1021/acs.jmedchem.0c01242

PMID: 33216538

Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.

Krämer A, Kurz CG, Berger BT, Celik IE, Tjaden A, Greco FA, Knapp S, Hanke T

Eur J Med Chem. 2020-8-23 . 208:112770 .doi: 10.1016/j.ejmech.2020.112770

PMID: 32883634

Selective targeting of the αC and DFG-out pocket in p38 MAPK.

Röhm S, Schröder M, Dwyer JE, Widdowson CS, Chaikuad A, Berger BT, Joerger AC, Krämer A, Harbig J, Dauch D, Kudolo M, Laufer S, Bagley MC, Knapp S

Eur J Med Chem. 2020-8-20 . 208:112721 .doi: 10.1016/j.ejmech.2020.112721

PMID: 33035818

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.

Bauer MR, Krämer A, Settanni G, Jones RN, Ni X, Khan Tareque R, Fersht AR, Spencer J, Joerger AC

ACS Chem Biol. 2020-3-20 . 15(3):657-668 .doi: 10.1021/acschembio.9b00748

PMID: 31990523

2019

A chemical toolbox for the study of bromodomains and epigenetic signaling.

Wu Q, Heidenreich D, Zhou S, Ackloo S, Krämer A, Nakka K, Lima-Fernandes E, Deblois G, Duan S, Vellanki RN, Li F, Vedadi M, Dilworth J, Lupien M, Brennan PE, Arrowsmith CH, Müller S, Fedorov O, Filippakopoulos P, Knapp S

Nat Commun. 2019-4-23 . 10(1):1915 .doi: 10.1038/s41467-019-09672-2

PMID: 31015424